Optical coherence tomography in multiple sclerosis

Elliot Frohman; Fiona Costello; Robert Zivadinov; Olaf Stuve; Amy Conger; Heather Winslow; Anand Trip; Teresa Frohman; Laura Balcer

doi:10.1016/S1474-4422(06)70573-7

Optical coherence tomography in multiple sclerosis

Elliot Frohman
, Fiona Costello
, Robert Zivadinov
, Olaf Stuve
, Amy Conger
, Heather Winslow
, Anand Trip
, Teresa Frohman
, Laura Balcer

Neurology

University of Texas Southwestern Medical Center
University of Ottawa
Department of Veterans Affairs
University College London
University of Pennsylvania

Research output: Contribution to journal › Review article › peer-review

155 Scopus citations

Abstract

We do not have currently satisfactory clinical and anatomical correlates to gauge disability in multiple sclerosis. Structural biomarkers (such as MRI) are hindered because they cannot precisely segregate demyelination from axonal elements of tissue injury within the CNS. Axonal degeneration in multiple sclerosis is related to irreversible disability, which suggests that the confirmation of neuroprotective strategies needs highly quantifiable measures of axon loss that can be correlated with reliable measures of physiological function. The coupling of quantifiable measures of visual function with ocular imaging techniques, such as optical coherence tomography, enables us to begin to understand how structural changes in the visual system influence function in patients with multiple sclerosis. In this review, we consider the usefulness of optical imaging of the retina as a biomarker for neurodegeneration in multiple-sclerosis.

Original language	English
Pages (from-to)	853-863
Number of pages	11
Journal	The Lancet Neurology
Volume	5
Issue number	10
DOIs	https://doi.org/10.1016/S1474-4422(06)70573-7
State	Published - Oct 2006

Access to Document

10.1016/S1474-4422(06)70573-7

Cite this

@article{f7fe698fcf0646c5a6bdb0d859533987,

title = "Optical coherence tomography in multiple sclerosis",

abstract = "We do not have currently satisfactory clinical and anatomical correlates to gauge disability in multiple sclerosis. Structural biomarkers (such as MRI) are hindered because they cannot precisely segregate demyelination from axonal elements of tissue injury within the CNS. Axonal degeneration in multiple sclerosis is related to irreversible disability, which suggests that the confirmation of neuroprotective strategies needs highly quantifiable measures of axon loss that can be correlated with reliable measures of physiological function. The coupling of quantifiable measures of visual function with ocular imaging techniques, such as optical coherence tomography, enables us to begin to understand how structural changes in the visual system influence function in patients with multiple sclerosis. In this review, we consider the usefulness of optical imaging of the retina as a biomarker for neurodegeneration in multiple-sclerosis.",

author = "Elliot Frohman and Fiona Costello and Robert Zivadinov and Olaf Stuve and Amy Conger and Heather Winslow and Anand Trip and Teresa Frohman and Laura Balcer",

year = "2006",

month = oct,

doi = "10.1016/S1474-4422(06)70573-7",

language = "English",

volume = "5",

pages = "853--863",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "Elsevier Ltd",

number = "10",

}

TY - JOUR

T1 - Optical coherence tomography in multiple sclerosis

AU - Frohman, Elliot

AU - Costello, Fiona

AU - Zivadinov, Robert

AU - Stuve, Olaf

AU - Conger, Amy

AU - Winslow, Heather

AU - Trip, Anand

AU - Frohman, Teresa

AU - Balcer, Laura

PY - 2006/10

Y1 - 2006/10

N2 - We do not have currently satisfactory clinical and anatomical correlates to gauge disability in multiple sclerosis. Structural biomarkers (such as MRI) are hindered because they cannot precisely segregate demyelination from axonal elements of tissue injury within the CNS. Axonal degeneration in multiple sclerosis is related to irreversible disability, which suggests that the confirmation of neuroprotective strategies needs highly quantifiable measures of axon loss that can be correlated with reliable measures of physiological function. The coupling of quantifiable measures of visual function with ocular imaging techniques, such as optical coherence tomography, enables us to begin to understand how structural changes in the visual system influence function in patients with multiple sclerosis. In this review, we consider the usefulness of optical imaging of the retina as a biomarker for neurodegeneration in multiple-sclerosis.

AB - We do not have currently satisfactory clinical and anatomical correlates to gauge disability in multiple sclerosis. Structural biomarkers (such as MRI) are hindered because they cannot precisely segregate demyelination from axonal elements of tissue injury within the CNS. Axonal degeneration in multiple sclerosis is related to irreversible disability, which suggests that the confirmation of neuroprotective strategies needs highly quantifiable measures of axon loss that can be correlated with reliable measures of physiological function. The coupling of quantifiable measures of visual function with ocular imaging techniques, such as optical coherence tomography, enables us to begin to understand how structural changes in the visual system influence function in patients with multiple sclerosis. In this review, we consider the usefulness of optical imaging of the retina as a biomarker for neurodegeneration in multiple-sclerosis.

UR - https://www.scopus.com/pages/publications/33750592482

U2 - 10.1016/S1474-4422(06)70573-7

DO - 10.1016/S1474-4422(06)70573-7

M3 - Review article

C2 - 16987732

AN - SCOPUS:33750592482

SN - 1474-4422

VL - 5

SP - 853

EP - 863

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 10

ER -

Optical coherence tomography in multiple sclerosis

Abstract

Access to Document

Other files and links

Fingerprint

Cite this